<?xml version='1.0' encoding='utf-8'?>
<document id="29733447"><sentence text="Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout."><entity charOffset="125-136" id="DDI-PubMed.29733447.s1.e0" text="Allopurinol" /></sentence><sentence text="Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of hyperuricemia and gout"><entity charOffset="36-45" id="DDI-PubMed.29733447.s2.e0" text="uric acid" /></sentence><sentence text=" This phase 1b, multiple-dose, drug-drug interaction study evaluated the pharmacokinetics, pharmacodynamics, and tolerability of verinurad in combination with allopurinol"><entity charOffset="159-170" id="DDI-PubMed.29733447.s3.e0" text="allopurinol" /></sentence><sentence text=" Adult males with gout were randomized to receive once-daily oral doses of allopurinol 300 mg or verinurad 10 mg alone for 7 days, allopurinol 300 mg + verinurad 10 mg on days 8 to 14, and the alternative single agent on days 15 to 21"><entity charOffset="75-86" id="DDI-PubMed.29733447.s4.e0" text="allopurinol" /><entity charOffset="131-142" id="DDI-PubMed.29733447.s4.e1" text="allopurinol" /><pair ddi="false" e1="DDI-PubMed.29733447.s4.e0" e2="DDI-PubMed.29733447.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29733447.s4.e0" e2="DDI-PubMed.29733447.s4.e1" /></sentence><sentence text=" Colchicine 0"><entity charOffset="1-11" id="DDI-PubMed.29733447.s5.e0" text="Colchicine" /></sentence><sentence text="6 mg was taken prophylactically for gout flares" /><sentence text=" Plasma/serum and urine samples were assayed for verinurad, allopurinol, oxypurinol (allopurinol active metabolite), colchicine (plasma only), and uric acid"><entity charOffset="60-71" id="DDI-PubMed.29733447.s7.e0" text="allopurinol" /><entity charOffset="73-83" id="DDI-PubMed.29733447.s7.e1" text="oxypurinol" /><entity charOffset="85-96" id="DDI-PubMed.29733447.s7.e2" text="allopurinol" /><entity charOffset="117-127" id="DDI-PubMed.29733447.s7.e3" text="colchicine" /><entity charOffset="147-156" id="DDI-PubMed.29733447.s7.e4" text="uric acid" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e0" e2="DDI-PubMed.29733447.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e0" e2="DDI-PubMed.29733447.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e0" e2="DDI-PubMed.29733447.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e0" e2="DDI-PubMed.29733447.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e0" e2="DDI-PubMed.29733447.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e1" e2="DDI-PubMed.29733447.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e1" e2="DDI-PubMed.29733447.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e1" e2="DDI-PubMed.29733447.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e1" e2="DDI-PubMed.29733447.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e2" e2="DDI-PubMed.29733447.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e2" e2="DDI-PubMed.29733447.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e2" e2="DDI-PubMed.29733447.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e3" e2="DDI-PubMed.29733447.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29733447.s7.e3" e2="DDI-PubMed.29733447.s7.e4" /></sentence><sentence text=" Safety was assessed by adverse events (AEs) and laboratory tests" /><sentence text=" Verinurad plasma exposure was unaffected by allopurinol"><entity charOffset="45-56" id="DDI-PubMed.29733447.s9.e0" text="allopurinol" /></sentence><sentence text=" Verinurad increased the maximum observed plasma concentration (Cmax ) for allopurinol by 33%; the area under the plasma concentration-time curve (AUC) was unaffected"><entity charOffset="75-86" id="DDI-PubMed.29733447.s10.e0" text="allopurinol" /></sentence><sentence text=" Oxypurinol Cmax and AUC were reduced 32% and 38%, respectively, by verinurad"><entity charOffset="1-11" id="DDI-PubMed.29733447.s11.e0" text="Oxypurinol" /></sentence><sentence text=" Colchicine plasma exposure was unaltered by verinurad"><entity charOffset="1-11" id="DDI-PubMed.29733447.s12.e0" text="Colchicine" /></sentence><sentence text=" The maximum decrease in serum urate was greater with verinurad + allopurinol (65%) than with verinurad (51%) or allopurinol (43%) alone"><entity charOffset="31-36" id="DDI-PubMed.29733447.s13.e0" text="urate" /><entity charOffset="54-77" id="DDI-PubMed.29733447.s13.e1" text="verinurad + allopurinol" /><entity charOffset="113-124" id="DDI-PubMed.29733447.s13.e2" text="allopurinol" /><pair ddi="false" e1="DDI-PubMed.29733447.s13.e0" e2="DDI-PubMed.29733447.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29733447.s13.e0" e2="DDI-PubMed.29733447.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29733447.s13.e0" e2="DDI-PubMed.29733447.s13.e2" /><pair ddi="false" e1="DDI-PubMed.29733447.s13.e1" e2="DDI-PubMed.29733447.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29733447.s13.e1" e2="DDI-PubMed.29733447.s13.e2" /></sentence><sentence text=" Compared with the baseline rate, the maximum rate of uric acid excreted in urine was +56% with verinurad, -46% with allopurinol, and unchanged with verinurad + allopurinol"><entity charOffset="54-63" id="DDI-PubMed.29733447.s14.e0" text="uric acid" /><entity charOffset="117-128" id="DDI-PubMed.29733447.s14.e1" text="allopurinol" /><entity charOffset="149-172" id="DDI-PubMed.29733447.s14.e2" text="verinurad + allopurinol" /><pair ddi="false" e1="DDI-PubMed.29733447.s14.e0" e2="DDI-PubMed.29733447.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29733447.s14.e0" e2="DDI-PubMed.29733447.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29733447.s14.e0" e2="DDI-PubMed.29733447.s14.e2" /><pair ddi="false" e1="DDI-PubMed.29733447.s14.e1" e2="DDI-PubMed.29733447.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29733447.s14.e1" e2="DDI-PubMed.29733447.s14.e2" /></sentence><sentence text=" No serious AEs, discontinuations due to AEs, or clinically significant laboratory abnormalities were noted" /><sentence text=" Despite decreased systemic exposure of allopurinol and oxypurinol in the presence of verinurad, the combination resulted in greater serum urate reduction compared with either drug alone and was well tolerated at the studied doses"><entity charOffset="40-51" id="DDI-PubMed.29733447.s16.e0" text="allopurinol" /><entity charOffset="56-66" id="DDI-PubMed.29733447.s16.e1" text="oxypurinol" /><entity charOffset="139-144" id="DDI-PubMed.29733447.s16.e2" text="urate" /><pair ddi="false" e1="DDI-PubMed.29733447.s16.e0" e2="DDI-PubMed.29733447.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29733447.s16.e0" e2="DDI-PubMed.29733447.s16.e1" /><pair ddi="false" e1="DDI-PubMed.29733447.s16.e0" e2="DDI-PubMed.29733447.s16.e2" /><pair ddi="false" e1="DDI-PubMed.29733447.s16.e1" e2="DDI-PubMed.29733447.s16.e1" /><pair ddi="false" e1="DDI-PubMed.29733447.s16.e1" e2="DDI-PubMed.29733447.s16.e2" /></sentence><sentence text="" /></document>